跳至主要内容
临床试验/EUCTR2013-003552-21-PL
EUCTR2013-003552-21-PL进行中(未招募)不适用

Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients with Type 2 Diabetes.

Eli Lilly and Company0 个研究点目标入组 540 人开始时间: 2014年4月23日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
540

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Men or women aged 18 to 80 years with T2DM. Eligibility criteria include: HbA1c =7.0% and =10.5% at screening and treated with diet and exercise alone or on a stable dose of metformin (=1000 mg/day) for 3 months prior to screening. BMI =23 and =45 kg/m2 at screening.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 337
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 38

排除标准

  • Patients are excluded from participation if they; are women of child bearing potential; used thiazolidinediones within 3 months prior to screening, or any other drugs for treatment of hyperglycemia (except metformin) within the prior 2 months; have used insulin for diabetic control for more than 6 consecutive days within the prior year; and if they have impaired renal function (serum creatinine >124 µmol/L [1.4 mg/dL] in women, >133 µmol/L [1.5 mg/dL] in men).

研究者

相似试验